Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).

被引：3

作者：

Chen, Robert W.

Ansel, Stephen Maxted

Zinzani, Pier Luigi

Vacirca, Jeffrey L.

Lopez-Guillermo, Armando

Hutchings, Martin

Jurczak, Wojciech

Hess, Georg

Le Gouill, Steven

Offner, Fritz

Santoro, Armando

Salles, Gilles A.

Stypinski, Darla

Laird, Douglas

Pavlov, Dmitri

Andreola, Giovanna

Fly, Kolette D.

Woolfson, Adrian

Collins, Graham P.

机构：

[1] City Hope Comprehens Canc Ctr, Duarte, CA USA

[2] Mayo Clin, Rochester, MN USA

[3] Univ Bologna, Inst Hematol L&A Seragnoli, Bologna, Italy

[4] North Shore Hematol Oncol Associates, Setauket, NY USA

[5] Hosp Clin Barcelona, Barcelona, Spain

[6] Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark

[7] Jagiellonian Univ, Krakow, Poland

[8] Johannes Gutenberg Univ Mainz, Mainz, Germany

[9] CHU Nantes, Nantes, France

[10] INSERM, UMR892, Nantes, France

[11] Ghent Univ Hosp, Gent, Germany

[12] Humanitas Canc Ctr, Humanitas Clin & Res Ctr, Rozzano, Italy

[13] Claude Bernard Univ Lyon, Hosp Civils Lyon, Canc Res Ctr Lyon, Lyon, France

[14] Pfizer Inc, San Diego, CA USA

[15] Pfizer Inc, New York, NY USA

[16] Pfizer Inc, Milan, Italy

[17] Pfizer Inc, Groton, CT 06340 USA

[18] Churchill Hosp, Oxford Canc & Haematol Ctr, Oxford, England

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.TPS7575

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS7575

引用

页数：6